Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban:Observations from the prospective EMIR Registry

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions